Erratum: AKT Inhibition in Solid Tumors With AKT1 Mutations(Journal of Clinical Oncology (2017) 35:20(JCO2017730143 )DOI: 10.1200/JCO.2017.73.0143);AKT inhibition in solid tumors with AKT1 mutations

Journal of Clinical Oncology

Volumn 35, Issue 20, 2017, Pages 2251-2259

  Hyman, David M ^a   Smyth, Lillian M ^a   Donoghue, Mark T A ^a   Chang, Matthew T ^a   Reichel, Jonathan B ^a   Bouvier, Nancy ^a   Selcuklu, S Duygu ^a   Soumerai, Tara E ^a   Torrisi, Jean ^a   Erinjeri, Joseph P ^a   Berger, Michael F ^a   Chandarlapaty, Sarat ^a   Solit, David B ^a,b   Baselga, Jose ^a   Taylor, Barry S ^a   Barrett, J Carl ^c   Dougherty, Brian ^c   Ambrose, Helen ^c   Foxley, Andrew ^c   Lindemann, Justin P O ^c   McEwen, Robert ^c   Pass, Martin ^c   Schiavon, Gaia ^c   Dean, Emma J ^d   Banerji, Udai ^e   Westin, Shannon N ^f   Bedard, Philippe L ^g   Bando, Hideaki ^h   El Khoueiry, Anthony B ⁱ   Mita, Alain ^j   Perez Fidalgo, Jose A ^k   Schellens, Jan H M ^l   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; AKT1 PROTEIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATININE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; 4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DNA; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ALLELIC IMBALANCE; ANUS CARCINOMA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ENDOMETRIUM CANCER; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; GENE FREQUENCY; GENE MUTATION; HEADACHE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; INTESTINE OBSTRUCTION; LIMB PAIN; LUNG ADENOCARCINOMA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MYALGIA; NAUSEA; NEXT GENERATION SEQUENCING; NOSE OBSTRUCTION; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEPSIS; SIDE EFFECT; SMALL INTESTINE DISEASE; SOLID MALIGNANT NEOPLASM; SOMATIC MUTATION; STOMATITIS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VOMITING; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ERUPTIONS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASMS; RASH; SIGNAL TRANSDUCTION;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DIARRHEA; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; HYPERGLYCEMIA; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIGNAL TRANSDUCTION;

EID: 85023764187     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02209     Document Type: Erratum

References (27)

1. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006
2. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501, 2002
3. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009
4. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004
5. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963, 2004
6. Rodon J, Dienstmann R, Serra V, et al: Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol 10:143-153, 2013
7. Yap TA, Bjerke L, Clarke PA, et al: Drugging PI3K in cancer: Refining targets and therapeutic strategies. Curr Opin Pharmacol 23:98-107, 2015
8. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012
9. Bleeker FE, Felicioni L, Buttitta F, et al: AKT1 (E17K) in human solid tumours. Oncogene 27: 5648-5650, 2008
10. Cohen Y, Shalmon B, Korach J, et al: AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 116: 88-91, 2010
11. Do H, Solomon B, Mitchell PL, et al: Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 1:14, 2008
12. Kim MS, Jeong EG, Yoo NJ, et al: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535, 2008
13. Chang MT, Asthana S, Gao SP, et al: Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34:155-163, 2016
14. Rudolph M, Anzeneder T, Schulz A, et al: AKT1 (E17K) mutation profiling in breast cancer: Prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer 16:622, 2016
15. Carpten JD, Faber AL, Horn C, et al: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444, 2007
16. Tamura K, Hashimoto J, Tanabe Y, et al: Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77:787-795, 2016
17. Davies BR, Greenwood H, Dudley P, et al: Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873-887, 2012
18. Elvin P, Palmer A, Womack C, et al: Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors. J Clin Oncol 32, 2014 (suppl; abstr 2541)
19. Banerji U, Dean EJ, Perez-Fidalgo JA, et al: A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. J Clin Oncol 33, 2015 (suppl; abstr 2500)
20. Cheng DT, Mitchell TN, Zehir A, et al: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17:251-264, 2015
21. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
22. Chandarlapaty S, Chen D, He W, et al: Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol 2:1310-1315, 2016
23. Parikh C, Janakiraman V, Wu WI, et al: Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci USA 109:19368-19373, 2012
24. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALKpositive lung cancer. N Engl J Med 368:2385-2394, 2013
25. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-1971, 2014
26. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714, 2012
27. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736, 2015